Navigation Links
Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
Date:9/29/2008

First complement inhibitor to be tested in AMD patients

LOUISVILLE, Ky., Sept. 29 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD) announced today that the Company's leading drug candidate, POT-4, has shown early positive safety results in its Phase I study. POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF). Based on this mechanism of action, POT-4 holds the potential to be effective against both dry and wet AMD.

"POT-4 has generated encouraging safety and tolerability data in this Phase I study and holds significant promise as a novel agent for treating AMD; a debilitating condition for which there is no cure," said Cedric Francois, President and CEO of Potentia. "As a result of the favorable early data, it was decided to expand the trial to permit further dose escalation, with the goal of prolonging the pharmacological benefit from POT-4. Potentia looks forward to the presentation of the Phase I data at a future medical conference and, with additional information gained from the extension of the study, to the initiation of Phase II trials in the future."

About AMD

AMD is the leading cause of blindness in the elderly of the western world and affects more than 10 million patients in the United States alone. The current standard of care for AMD relies primarily on angiogenesis inhibitors, an approach geared towards the approximately 10-15% of AMD patients with complications resulting from ocular angiogenesis (growth of new blood vessels and bleeding in the back of the eye). No drug currently on the market has been approved for the treatment of the remaining patients, who suffer from the so-called "dry" form of the disease.

Abo
'/>"/>

SOURCE Potentia Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
4. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
5. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
6. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
7. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
8. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
9. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
10. Potential Early Warning System for Lung Cancer Identified
11. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/23/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... development and sale of patented biopharmaceutical medicine, modernized traditional ... (API) today announced the business and development progress at ... 1. Following the September 2014 JCM application (No. 51268) ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
(Date:12/26/2014)... said that nothing makes a lady feel more feminine than ... shows its new selection of navy cocktail dresses , ... navy cocktail gowns are the cornerstones of the site’s cocktail ... dresses in bright neon colors can be dressed up or ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2
... 11, 2007 Physicians at UT Southwestern Medical Center are the ... small radioactive pellet, or seed, is implanted into a mass or ... surgical removal. , During the procedure, a radiologist uses a needle ... grain of rice, into the mass. Once lodged, surgeons use a ...
... Oct. 11, 2007 Dr. Beth Levine, professor ... division of infectious diseases at UT Southwestern Medical Center, ... today. , Dr. Levine is one of 15 new ... a philanthropic organization that promotes biomedical research. Her appointment ...
... 1999 Equity ... Incentive Plan, ... leading provider of state-of-the-art diagnostic and,digital imaging systems directed towards women,s ... that,Hologic stockholders vote "FOR" the Company,s proposed merger with Cytyc,Corporation (Nasdaq: ...
... Just released trial data show high acceptance of interactive ... system, two-thirds of patients prefer automated system, ... a developer,of advanced interactive voice response (IVR) solutions, today ... (IVRS) optimized,for use in the healthcare environment. CallAssure uses ...
... Step-by-Step Process and Provides Sample Appeal,Letter, WASHINGTON, Oct. ... peace of mind that they will have,access to the ... the medicine that,s prescribed by the doctor isn,t always,covered. ... need,to know what they can do about it., ...
... Quality of Health Care, PITTSBURGH, Oct. 11 ... select hospitals in Western Pennsylvania as part of ... line- associated bloodstream infections. Central lines are ... nutrition to critically ill patients through vessels that ...
Cached Medicine News:Health News:New 'seed' therapy helps pinpoint breast tumors with more accuracy 2Health News:UT Southwestern researcher named Howard Hughes Medical Institute investigator 2Health News:UT Southwestern researcher named Howard Hughes Medical Institute investigator 3Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 2Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 3Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 4Health News:Vocantas CallAssure provides hospitals with automated solution for post-discharge patient follow-up 2Health News:Vocantas CallAssure provides hospitals with automated solution for post-discharge patient follow-up 3Health News:New Resource Explains What Seniors Can Do if Medicare Denies Coverage of Their Medicines 2Health News:Highmark's Hospital Pay-for-Performance Program Demonstrates Impressive Results 2Health News:Highmark's Hospital Pay-for-Performance Program Demonstrates Impressive Results 3
Sony DSR-20MD is the right choice If you need digital recording capability. It accepts both s-video and composite inputs....
The VISERA Multi-Specialty Digital Imaging Platform is the world's first integrated system of digital rigid, deflectable tip and flexible videoscopes for use in operating room endosurgery as well as ...
... for clinical image management. Mediscan is ... management system derived from extensive experience ... to capture, organize, and distribute high ... with minimum effort. Can be connected ...
... probes feature response times in ... real-time monitoring of physiological events. ... measurements of pO2, blood perfusion ... from the same tissue site ...
Medicine Products: